SCHEMBL1302385

SCHEMBL1302385

CCn1nnc(CCNC(=O)Nc2cn3cc(-c4cncc5ccccc45)ccc3n2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.45
PIK3CA P42336 2/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CB P42338 1/20 0.39
CLK1 P49759 1/20 0.39
CLK2 P49760 1/20 0.39
PI4KB Q9UBF8 1/20 0.39
LRRK2 Q5S007 5/20 0.38
CCNC P24863 3/20 0.37
CDK8 P49336 3/20 0.37
ABL1 P00519 3/20 0.37
FLT3 P36888 1/20 0.35
MYLK Q15746 1/20 0.35
AURKB Q96GD4 1/20 0.35
CILK1 Q9UPZ9 1/20 0.35
CDK11A Q9UQ88 1/20 0.35
ROCK2 O75116 1/20 0.35
NAMPT P43490 1/20 0.35
MAPK13 O15264 1/20 0.35
BRAF P15056 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1302602 0.83 MAP3K5 (0.51) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1302528 0.82 PIK3CA (0.44) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1302835 0.81 MAPK1 (0.43) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1302670 0.80 MAP3K5 (0.44) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1303576 0.80 PIK3CA (0.42) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1303089 0.79 CREBBP (0.42) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1302957 0.78 LRRK2 (0.42) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1303285 0.77 BRAF (0.43) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1303491 0.76 PIK3CA (0.41) PIK3CGPIK3CAPIK3CDPIK3CBCLK1
SCHEMBL1302406 0.76 HPGD (0.40) PIK3CGPIK3CAPIK3CDPIK3CBCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2178868-A1 BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Novartis Ag (CH) 2010-04-28 EP claimed
WO-2009010530-A1 BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS NOVARTIS AG (CH) 2009-01-22 WO claimed
US-8053574-B2 Organic compounds NOVARTIS AG (CH) 2011-11-08 US disclosed
US-20100197682-A1 Organic Compounds NOVARTIS AG 2010-08-05 US disclosed
EP-2178868-A1 BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Novartis Ag (CH) 2010-04-28 EP disclosed
WO-2009010530-A1 BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS NOVARTIS AG (CH) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197682-A1 Organic Compounds PIK3CA, PI4KA, PI4KB PIK3CG 11/4885PIK3CA 1/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.